Economic evaluation supports prophylactic naldemedine for opioid-induced constipation in cancer palliative care

Дата публикации: 11-07-2026 22:00:01

Although opioids remain indispensable for pain relief in patients with advanced cancer, their use frequently results in OIC, which can substantially reduce quality of life and, in some cases, compromise the continuation of optimal pain management. Naldemedine, a peripherally acting μ-opioid receptor antagonist, is used to treat OIC by preserving physiological bowel motility without interfering with central analgesia.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	FDA Approves Additional Naloxone Nasal Spray for Opioid Overdose	0	5	02-07-2026
2	Cost-Effectiveness of Perioperative Pembrolizumab in Locally Advanced Head and Neck Cancer	0	7	02-07-2026
3	Opioid Use and Pain Resolution for Acute Pain Among Opioid-Naive Patients	0	7	07-07-2026
4	Precision drug olaparib may be effective without hormone therapy for some men with biochemically recurrent prostate cancer	0	7	22-08-2024
5	Precision therapy for metastatic prostate cancer improves survival	2	7	20-08-2024
6	Власти России докупят один из дефицитных препаратов для онкобольных	0	0	10-12-2020
7	Study solves testosterone's paradoxical effects in prostate cancer	0	8	04-09-2024
8	Natural sleeping tablet melatonin could also ease chronic pain - so why is the 50p pill so difficult to get hold of in the UK?	0	7	01-07-2026
9	Novel biomarker research offers new hope in the fight against colorectal cancer	7	8	06-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 5. Информативность: 7. Источник: medicalxpress.com.